HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.

ABSTRACT:

Background

Some observational studies have found increased HIV risk associated with self-reported use of injectable depot medroxyprogesterone acetate. Testing blood samples for medroxyprogesterone acetate (MPA), the progestin in depot medroxyprogesterone acetate, permits validation of self-reported data, and exploration of whether potential HIV risk is correlated with MPA levels, which are highest soon after injection.

Methods

We conducted a case-control study testing archived serum from women who participated in three longitudinal studies of HIV prevention in East and southern Africa. Case samples, from women who acquired HIV, were from visits that occurred at or immediately prior to the first evidence of HIV infection. Secondary analyses restricted to case samples collecte

SUBMITTER: Heffron R 

PROVIDER: S-EPMC6399047 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature